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ABSTRACT:
Objective. Maternal administration of betamethasone to enhance fetal lung maturation for women who threaten preterm labor is common clinical practice. However, recommendations regarding the choice of betamethasone formulations for perinatal use are vague. The disposition of betamethasone from two commonly used antenatal formulations is poorly understood. We therefore designed a study to capture the true pharmacokinetic profiles of betamethasone from these fast acting and dual release formulations. Methods. Betamethasone in sheep plasma was measured by a newly designed highly sensitive liquid chromatography tandem mass spectrometry assay after intramuscular injection (n = 4) of 0.25 mg/kg of betamethasone phosphate and 0.5 mg/kg betamethasone phosphate/acetate formulations. Compartmental modeling was performed using the ADAPT II program. Results. Betamethasone pharmacokinetics could be captured for 24 hours for the phosphate and for 5 days for the phosphate/acetate formulations. The phosphate formulation profile appeared like a traditional Bateman function with a terminal half-life of 4 hours whereas the phosphate/acetate formulation produced a biexponential decline with a terminal half-life of 14 hours. The latter is much longer than commonly reported and has been missed in the literature due to assay limitations. Extrapolations to humans indicate that although both formulations might have similar therapeutic indices, the dual formulation might be associated with a lower safety profile. Conclusion. In light of this newly identified long terminal half-life for the betamethasone dual formulation, dosing practices for betamethasone in pregnancy need to be reassessed.
DMD #4309
Preterm birth occurs in about 10% of pregnancies and complications associated with prematurity, especially respiratory distress syndrome, are the leading cause of mortality in prematurely born infants (NIH Consensus Panel, 1995) . Betamethasone is administered maternally to enhance fetal lung maturation in women who threaten preterm labor during 24-34 weeks gestation. The NIH recommends administration of two maternal intramuscular injections of 12-mg betamethasone 24 hours apart for this condition. Although the doses of betamethasone are stated, the exact formulation recommendation is not clear. Betamethasone is available as a fast releasing phosphate ester prodrug formulation and as a dual acting suspension formulation containing phosphate and acetate ester prodrugs. Both formulations have been tested in clinical trials and have been shown to be efficacious in producing precocious fetal lung maturation (Liggins and Howie, 1972; Gamsu et al., 1989) . However, there is controversy regarding the betamethasone releasing properties of the acetate prodrug and a recent meta-analysis suggests that this prodrug is probably of little therapeutic benefit for antenatal use (Jobe and Soll, 2004) . Although the release properties of the acetate prodrug have been questioned, long duration studies looking at the release pattern of betamethasone from this prodrug do not exist. Furthermore, traditional chromatographic assays for betamethasone in animal studies suffer from sensitivity and sample stability issues that were raised in a recent meta-analysis (Samtani et al., 2004a) . These problems remain unresolved and we therefore designed a study to capture the true pharmacokinetic profiles of betamethasone from the two formulations. The study design and rationale were as follows: a) The most commonly utilized animal model for fetal maturation studies is the pregnant sheep (Dunlop et al., 1997) and hence the pharmacokinetic investigation was DMD #4309 conducted in ewes. b) The formulations were compared in non-pregnant animals. Our meta-analysis (Samtani et al., 2004a) has pointed out that complete pharmacokinetic characterization of drugs in pregnancy requires complicated study designs involving maternal/fetal dosing and sampling. Corticosteroid studies in sheep pregnancy are complicated by the use of tocolytics to prevent premature labor, require technical experience with ultrasound guided fetal injections, and require a 100-120 day wait period to reach the appropriate gestational age for corticosteroid studies. We aspired to capture betamethasone release from the acetate prodrug and this objective can be easily accomplished by studying pharmacokinetics in the uncomplicated non-pregnant state. c)
The dual acting formulation was evaluated as a single intramuscular injection of 0.5 mg/kg. This dose is higher than that recommended by the NIH in humans (0.17 mg/kg), but has been found to be the dosage in sheep that consistently produces preterm fetal lung maturation (Moss et al., 2001) . This is also the highest dose level that can be investigated because it is associated with an injection size of 4-6 mL, which is the maximum recommended intramuscular administration volume (Rodger and King, 2000) . The use of a high dose is necessary to capture the low-level betamethasone release that could occur from the acetate prodrug. The dose of the fast acting phosphate formulation was chosen to be 0.25 mg/kg. The 0.5 mg/kg injection of the dual formulation contains 0.25 mg/kg phosphate prodrug. Thus, betamethasone release by the acetate prodrug can be easily obtained by simple subtraction of the two profiles obtained from the two dose groups. d)
We designed a liquid chromatography tandem mass spectrometry (LC/MS/MS) assay for measuring betamethasone that is capable of measuring low drug concentrations. This would help with the aim of measuring slow release of betamethasone from the acetate DMD #4309
Methods
Materials. Sodium arsenate heptahydrate, potassium fluoride, formic acid and prednisolone internal standard were purchased from Sigma-Aldrich (St. Louis, MO). The source for betamethasone was Steraloids Inc (Newport, RI). HPLC grade water and acetonitrile were from Burdick & Jackson (Muskegon, MI). Methanol was obtained from EMD Chemicals (Gibbstown, NJ). Phosphoric acid was from JT Baker (Phillipsburg, NJ) and ammonium formate was supplied by Fluka Biochemika (Buchs, Switzerland).
Clinically used formulations for betamethasone phosphate (Celestan solubile) and betamethasone phosphate/acetate (Celestan depot) were from Essex Pharma in Munich,
Germany.
Betamethasone Pharmacokinetic Study. Experimental procedures were approved by the Animal Care and Use Committee of the University of Wyoming, Laramie, WY. Eight Western Range ewes were weighed and brought into the animal facilities one day before the experiment. The animals were housed in outside pens and had ad libitum access to hay, hay cubes and water. On the day of the experiment, ewes were randomly assigned to two groups of four animals and were treated as follows.
Group 1 received 0.25 mg kg -1 betamethasone phosphate and the mean body weight of the animals in this group was 70 ± 6.4 kg (mean ± SD). Group 2 received 0.5 mg kg -1 betamethasone phosphate / acetate mixture and the average body weight of the animals was 68 ± 9.4 kg. The injections were administered intramuscularly into the gluteal muscle at 8:30 AM in order to minimize the impact of circadian cortisol rhythms on the results. In both groups, blood samples were taken directly from the jugular vein at 15, 30, 45, 60, 90 min and at 3, 5, 8, 12 , 24 h after each injection. In the dual formulation group, This article has not been copyedited and formatted. The final version may differ from this version. (Samtani et al., 2004a) .
Sample Preparation. Sample processing was carried out in lab plasticware to prevent the known adsorption of steroids to glassware (Makin et al., 1995) . Non-specific adsorption can affect analyte sensitivity and recovery in the low-level analysis described in this work and the hydrophobicity of the polypropylene plastic surface helps reduce sample adsorption problems (Tsutsumi et al., 2003) . Sample preparation involved adding 0.5 mL 4% phosphoric acid to 0.5 mL plasma sample in polypropylene tubes. This makes the samples less viscous and can free up the protein bound drug in plasma (Ding and Neue, 1999) . 50 µL of a methanolic stock (1 µg/mL) of prednisolone was added as internal standard. After thorough mixing, samples were centrifuged at 8000g for 20 minutes and then subjected to solid phase extraction using Oasis HLB, 1 cc 30 mg Elut SPS 24 solid phase extraction manifold (Varian, Palo Alto, CA). The samples were extracted using the generic Oasis HLB procedure recommended by the manufacturer for 1 cc cartridges. Briefly, the SPE cartridge was pre-conditioned with 1 mL of methanol, followed by 1 mL of water. One ml of the processed sample was pulled through the cartridge, the cartridge was washed with 1 mL of 5% methanol in water and elution was performed with 1 mL methanol. The methanolic eluant was dried at 50°C under a gentle nitrogen stream and the dried residue was reconstituted with 50% 10 mM ammonium formate and 0.1% formic acid/50% acetonitrile. The reconstituted samples were transferred into 0.5 mL polypropylene tubes, centrifuged at 16000g for 10 min at 4°C and finally injected into the LC/MS/MS.
Plasma based standards and quality control (QC) standards were prepared from blank sheep plasma. Betamethasone methanolic stock solutions were added to polypropylene tubes and dried under nitrogen. Appropriate volumes of plasma were added, the tubes vortexed, and QC/standards were aliquoted at > 0.5 mL into 1.5 mL polypropylene tubes and stored at -20°C. The assay covers a concentration range of 0.1-100 ng/mL for betamethasone. Samples expected to have concentration greater than 100 ng/mL were diluted with an appropriate volume of blank plasma. Standards were run on a daily basis and samples and QC were quantified using a quadratic regression curve of analyte to internal standard area ratio vs. concentration with a weighting factor of 1/Y 2 .
The assay produced standard curves with r 2 ≥ 0.99, had an inter-and intra-assay accuracy and precision of ≤ 14%, and offered almost complete extraction recovery for betamethasone.
This article has not been copyedited and formatted. The final version may differ from this version. Applied Biosystems PE/Sciex API 3000 mass spectrometer (Foster City, CA) using a turbo-ion spray source. The system control and data analysis were executed using the Analyst software (Applied Biosystems, Version 1.4). Chromatography was performed on a C 8 Hydrobond AQ column (particle size 3 uM, 2.1 x 150 mm, MAC-MOD Analytical Inc, Chadds Ford, PA) equipped with a ColumnSaver pre-column filter (MAC-MOD Analytical Inc). The mobile phase flow rate was 0.2 mL/min with eluant A consisting of 10 mM ammonium formate and 0.1% formic acid and eluant B consisting of acetonitrile.
The mobile phase flow design was as follows: 0-4.5 min 40% A/60% B, 4.6-6.0 min: 10% A/90% B to allow system cleanup, followed by a 4 min equilibration step at 40%
A/60% B. The mass spectrometer was operated in the positive ionization mode. The optimal ion pairs, declusturing potential, collision energy, collision exit potential, focusing potential, and excitation potential for betamethasone and prednisolone were found to be 393.3/373.3, 35V, 15V, 23V, 300V, 10V and 361.3/343.5, 25V, 15V, 20V, 300V, 10V, respectively. High purity nitrogen was used as the curtain and collision gas.
The source temperature was set at 350°C.
Pharmacokinetic Analysis. Mean betamethasone concentration profiles as a function of time (t) after administration of the two formulations were fitted simultaneously using the models shown in Figure 1 . The differential equations and their initial conditions used in the fitting procedure were as follows: project human profiles, drug concentrations need to be scaled to the clinical dose and correction made for plasma protein binding to obtain free drug concentrations that drive corticosteroid effects. An estimate of possible fetal drug exposure can be obtained by recognizing that the placental barrier creates a fetal to maternal betamethasone concentration gradient in humans of approximately one-third (Samtani et al., 2004a) . The correction factors needed to make human extrapolations are provided in Table 1 . The calculations were performed in an Excel spreadsheet (Microsoft Excel software, Microsoft, Redmond, WA) by multiplying the combined correction factors with the appropriate predicted concentrations from the model fittings. To understand the relationship between projected concentrations and clinical outcome, efficacy and toxicity indices were calculated. Adrenal suppression was considered as a biomarker for assessing corticosteroid adverse effects. Prednisolone IC 50,Free (free drug concentration causing 50% inhibition of cortisol synthesis rate) for adrenal suppression is known to be 1 ng/mL (Wald et al., 1992) . Betamethasone, based on relative receptor affinity values, has a 3.6-fold higher affinity than prednisolone for the glucocorticoid receptor (Mollmann et al., 1995) . Knowledge of the relative receptor affinities and prednisolone IC 50,Free allows for calculation of a 0.3 ng/mL value for betamethasone IC 50,Free (Mager and Jusko, 2002) . et al., 1986) . Dexamethasone has 1.7-fold higher affinity than betamethasone for binding to the glucocorticoid receptor in the human lung (Mollmann et al., 1995) . This information allows calculation of a dissociation constant value of 8.5 nM (3 ng/mL) for betamethasone. Extrapolated maternal/fetal profiles for the two formulations were compared to this efficacy threshold to discern which of the two formulations may have a better efficacy profile. The longer the concentrations stay above the efficacy threshold, the greater is the potential for producing fetal lung maturation. Extrapolated free betamethasone concentrations in fetal plasma can be directly compared to the This article has not been copyedited and formatted. The final version may differ from this version. (Figure 2) . The assay was adapted from a method described for rat plasma samples (Tamvakopoulos et al., 2002 ). An important change was made wherein the assay was scaled up to make it suitable for plasma samples from sheep.
Tamvakopoulos et al. measured betamethasone in small volume rat plasma samples and hence used a 96-well miniaturized HLB Oasis extraction format. Sample volume was not a limitation in our study and we wished to measure extremely low drug concentrations.
We therefore used the HLB Oasis cartridge format for extracting plasma samples which involved a ten-fold larger sample volume (500 vs. 50 µL). By using a larger sample volume we were able to reduce the assay lower limit of quantification of 2 ng/mL reported by Tamvakopoulos et al. to 0.1 ng/mL. During the preparation of this manuscript two other methods describing LC/MS/MS analysis of betamethasone in plasma were published (Taylor et al., 2004; Luo et al., 2005) . These methods monitor different daughter ions in tandem MS for betamethasone and make use of longer liquid-liquid extraction based sample preparation methods. However, both these methods are similar to our assay in terms of assay sensitivity, accuracy, precision, specificity and quantifiable concentration range. recent meta-analysis (Samtani et al., 2004a) , show a distinct absorption/formation phase.
The latter is indicative of lack of sample instability artifacts, which were prevented by addition of enzyme inhibitors. Both formulations produced a peak concentration of about 180 ng/mL at 1-1.5 hour, which reflects the fast input from the phosphate prodrug (Table   2: Table 2 and the < 15% coefficient of variation for all fitted parameters is indicative of excellent model performance. Figure 3 agreement at the early time points between the two datasets, which can be attributed to lack of sample stabilization in the pregnant animal data. Apart from the early disconnect in concentrations, there is reasonable agreement between the two datasets. This pharmacokinetic trait of similarity in betamethasone disposition between the pregnant and non-pregnant states has also been observed in humans (Benet et al., 1996) . We have recently shown that sheep pharmacokinetic profiles for betamethasone in pregnant sheep are a good representation of human profiles in pregnancy (Samtani et al., 2004a) .
Effect of Pregnancy on Betamethasone Pharmacokinetics.
Minimal scaling of pharmacokinetics is required because of similarity in body weights.
The resemblance between humans and sheep for betamethasone pharmacokinetics during the pregnant and non-pregnant states allows the use of sheep as excellent animal model for anticipating betamethasone disposition during pregnancy in humans.
Extrapolated Human Profiles. Extrapolations to the human situation are shown
in Figure 4 and they indicate that the two formulations given at equal doses will produce markedly different profiles in the maternal and fetal circulations. The 12 mg dose of betamethasone in the form of the phosphate prodrug would generate higher peak levels both in the mother and the fetus and produce a steep decline in concentrations. In contrast 12 mg of the dual formulation (8 mg betamethasone phosphate equivalent to 6 mg betamethasone and 6 mg betamethasone acetate) would produce lower peak concentrations in the maternal and fetal circulations. However, maternal and fetal profiles would have a prolonged terminal half-life because of the sustained-release nature of the acetate prodrug.
The delayed release property of the dual formulation causes betamethasone concentrations to stay above the proposed toxicity threshold for a longer period in This article has not been copyedited and formatted. The final version may differ from this version. maternal and fetal plasma and this sustained exposure is shorter in the fetal than in the maternal circulation. This is because restricted placental access of betamethasone produces lower peak concentrations in the fetus and hence it takes a shorter duration of time for betamethasone levels to fall below the toxicity threshold.
Finally, the time of exposure to therapeutic betamethasone concentrations in the fetal circulation is similar. Both formulations produce profiles that cross the therapeutic threshold at approximately the same time.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Choice of LC/MS/MS for Analysis. Commonly used HPLC assays for corticosteroids have a lower limit of quantitation of 10 ng/mL (Jusko et al., 1994) . Other methods based on gas chromatography/mass spectrometry and fluorescence detection, although offering highly specific and sensitive analysis, require derivatization (Frerichs and Tornatore, 2004) . Bioanalytical methods based on LC/MS/MS represent the most specific and sensitive methods for steroid analysis (Lai et al., 2002) . This technique coupled with solid phase extraction combines the attributes of rapidity, easy processing, accuracy, specificity, sensitivity and precision without the need for sample derivatization.
We therefore assayed betamethasone in sheep plasma using a solid phase extraction LC/MS/MS method, which allowed measurement of slow betamethasone release from the acetate prodrug.
Release Rates of Active Steroid by Betamethasone Prodrugs. It is generally
accepted that the conversion of the acetate and phosphate prodrugs to the active corticosteroid is a relatively fast process. Studies in rodents have shown that the acetate prodrug administered intravenously (dissolved in dimethylsulfoxide containing saline) produces corticosteroid pharmacokinetics that are identical to those produced by an intravenously administered phosphate prodrug (Ogiso et al., 1987) . The inability of the conversion process to serve as a rate-limiting step is not surprising because activating enzymes such as phosphatases and esterases are highly efficient and ubiquitous (Krise et al., 1999) .
The release rate of betamethasone from the two prodrugs is controlled by their physicochemical properties. The phosphate prodrug being highly ionized has an aqueous This article has not been copyedited and formatted. The final version may differ from this version. (Harvey, 1975) . It is injected as a solution and exhibits rapid absorption after intramuscular administration. Consequently, the disposition processes controlling betamethasone pharmacokinetics dictate the terminal decline in concentrations after injection of the phosphate prodrug. In contrast, the acetate prodrug is highly hydrophobic, has an aqueous solubility of 30 µg/mL (Kabasakalian et al., 1966) , and is administered intramuscularly as a suspension. The > 20000-fold lower solubility creates dissolution rate limited absorption of the acetate prodrug. It has to first dissolve in the fluids of the intercellular space of muscle fibers before it can diffuse into the vascular space (Hirano et al., 1981) . For practically water insoluble molecules in vitro solubility is directly correlated to in vivo absorption after intramuscular injection of an aqueous suspension (Zuidema et al., 1994) . The solubilization of the suspension is often the slowest event amongst the ADME processes after intramuscular injection. The rate limiting solubilization process is reflected in the terminal slope of the pharmacokinetic profile leading to flip-flop kinetics. Furthermore, inter-species differences in the terminal half-life are not expected since the dissolution process at the injection depot governs the terminal decline (Zuidema et al., 1994) . Thus the long half-life observed for betamethasone in this study after injection of the dual formulation may also occur in humans. We believe that the long half-life has not been detected previously after intramuscular administration because of assay and sampling limitations. Furthermore, the acetate prodrug is also only 62% bioavailable as compared to the phosphate prodrug (Table 2 : F BMa /F BMp = 62.3 %). This is not surprising because highly lipophilic compounds produce biphasic absorption after intramuscular injection, where the second slow phase is exceptionally difficult to capture leading to the conclusion of incomplete This article has not been copyedited and formatted. The final version may differ from this version. (Zuidema et al., 1994) . This slow second phase is thought to produce a "hang-over effect", which leads to drug levels that are probably not therapeutically useful and may be a source of unwanted side effects (Zuidema et al., 1994) . The possibility even exists that some drug continues to be absorbed beyond 120 hr with a third phase of release (Figure 2) .
Biexponential Decline Following the Dual Formulation. Multiexponential decline patterns for betamethasone can be observed due to various reasons. Possibilities include: i) Spurious overestimation of concentrations due to sample instability (Samtani et al., 2004b) , ii) Tissue distribution, iii) Dual betamethasone input. It is often assumed that the acetate prodrug does not release betamethasone and the biexponential profile has been attributed to tissue distribution (Samtani et al., 2004a) . However, Figure 2 clearly indicates that the acetate does have sustained-release properties and the phosphate prodrug profile lacks an obvious distribution phase. Furthermore, we prevented artifactual overestimation of concentrations by sample stabilization and therefore the most probable explanation for betamethasone multiexponentialilty is dual steroid input.
This probably indicates that estimates of tissue distribution volumes and clearances reported in the literature need to be interpreted with caution because they may have been estimated inaccurately due to model misspecification.
Observation of a biexponential decline pattern is a typical feature of analytes with dual input. A classic example is metabolite kinetics observed after oral administration of a drug exhibiting high oral first-pass effect (Rowland and Tozer, 1995) . The mathematical rationale behind the biexponential decline can be readily understood by This article has not been copyedited and formatted. The final version may differ from this version. Reconciling Different Beliefs about Acetate Prodrug Release. Studies that have concluded that the acetate prodrug does not release betamethasone were short duration studies that spanned 8-10 hours (Petersen et al., 1984) . (Ballard et al., 1975) . Based on the half-life obtained from this study and information from betamethasone phosphate studies in non-pregnant subjects Ballard has stated that the dual formulation does have sustained-release properties (Ballard, 1986; Ballard and Ballard, 1995) . The terminal half-life of 6 hours reported by Ballard is the widely accepted half-life for betamethasone after administration of the dual formulation (Dudley et al., 2003 , Padbury et al., 1996 . Although, Ballard made an insightful and This article has not been copyedited and formatted. The final version may differ from this version. accurate conclusion about the dual release properties of the phosphate/acetate formulation, the commonly accepted half-life is probably incorrect. Based on the data in Figure 2 , it is obvious that the true terminal decline phase of betamethasone from the acetate prodrug will be missed if the profile is followed for any duration less than 2-3 days. In light of this new finding, dosing recommendations for betamethasone formulations need to be reassessed. This finding is particularly important because in the United States, the only injectable form of betamethasone recommended and available for antenatal use is the dual formulation. Betamethasone sodium phosphate injection now appears in the "discontinued" section of FDA's Orange Book because Schering-Plough discontinued the manufacture of this product in May 2002. Furthermore, many clinicians have adopted the practice of giving multiple doses (as many as 11 repeat courses) of betamethasone to enhance fetal lung maturation (Andrews and Matthews, 2003) . The prolonged half-life for betamethasone from the intramuscular depot combined with multiple-dosing can have accumulative and unfavorable effects in the mother and fetus and this will be discussed below. phosphate prodrug. The mother serves as a delivery mode and reservoir for the steroid and is exposed to betamethasone levels three times higher than the fetus. The practice of exposing the parturient mother to steroid levels that are of no therapeutic benefit to her and probably lead to adverse effects is unfortunate. Reassessment of use of this dual formulation regimen during pregnancy is warranted.
Implications of a Prolonged
Several assumptions have been made in arriving at the conclusion regarding the reassessment of corticosteroid dosing regimens during pregnancy. These conclusions need to be supported by additional long duration experimental data on corticosteroid pharmacokinetics, adrenal suppression, and fetal drug exposure from different formulations during pregnancy. Corticosteroids have been used for precocious induction of fetal lung maturation for over thirty years. However, the pharmacokinetic, pharmacodynamic and toxicodynamic properties of corticosteroids in pregnancy are poorly understood and can be improved by well-designed mechanistic studies using modern analytical tools.
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